Abstract: 8-Hydroxy quinoline derivative compounds for enhancing telomerase reverse transcriptase (TERT) expression, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.
Type:
Grant
Filed:
May 18, 2011
Date of Patent:
July 18, 2023
Assignee:
Sierra Sciences, Inc.
Inventors:
William H. Andrews, Lancer K. Brown, Laura A. Briggs, Federico C. A. Gaeta, Hamid Mohammadpour, Mieczyslaw A. Piatyszek
Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).
Type:
Grant
Filed:
July 9, 2021
Date of Patent:
July 11, 2023
Assignees:
Fimbrion Therapeutics, Inc., GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.
Abstract: Processes for converting lignocellulose to feedstock and downstream products are disclosed. The processes may include acid treatment of lignocellulose to produce a fermentation feedstock. In various instances, the processes include recovery or recycling of acid, such as recovery of hydrochloric acid from concentrated and/or dilute streams. Downstream products may include acrylic acid-based products such as diapers, paper and paper-based products, ethanol, biofuels such as biodiesel and fuel additives, and detergents.
Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, for example, one or more agents that decrease the concentration of cyclooxygenase-2, decrease the concentration of transient receptor potential cation channel subfamily V member 1, and/or decrease calcitonin gene-related peptide concentration. In some embodiments, a composition as provided herein includes apigenin present in an amount of about 1% to about 5% w/w of the composition; and hesperidin present in an amount of about 90% to about 99% w/w of the composition. Such compositions are useful for decreasing joint pain and/or inflammation.
Type:
Grant
Filed:
September 3, 2020
Date of Patent:
May 9, 2023
Assignee:
BioRelief, LLC
Inventors:
Gary Jeffery Ramey, V. A. Shiva Ayyadurai, Prabhakar Deonikar
Abstract: Provided herein are compounds having the structure of Formulas A-D and compositions thereof for use in the detection and quantification of viral neuraminidase. In particular, the compounds may be useful for the evaluation of viral strains and for vaccine evaluation.
Abstract: The present disclosure relates to a composition comprising (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof as an active ingredient. In addition, it relates to a method for preventing or improving menopausal symptoms, which comprises administering an effective amount of (20S,24R)-6-O-?-D-glucopyranosyl(1?2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof to a subject in need thereof. The novel ginsenoside has a superior effect of preventing or improving menopausal symptoms with a low risk of breast cancer.
Abstract: A number of triterpene saponin variants with different modifications on their central glycosyl ester linkage are described. Also described are methods of making and method of using such triterpene saponin variants.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
April 18, 2023
Assignee:
Memorial Sloan-Kettering Cancer Center
Inventors:
Derek S. Tan, David Y. Gin, William E. Walkowicz, Alberto Fernandez-Tejada, Govindaswami Ragupathi
Abstract: Provided herein is chitosan dually derivatized with arginine and gluconic acid; and methods of making and using the same, e.g., for gene delivery in vivo.
Abstract: Disclosed is synthesis of an O-Antigen oligosaccharide compound of Helicobacter pylori serotype O2, belonging to the field of organic synthesis. The disclosure obtains O-antigen disaccharide to tetracosasaccharide of Helicobacter pylori serotype O2 by chemical synthesis. A chemical synthesis method which is quite conducive to production of a glucose-?-lglucosidic bond is developed in the disclosure by a protectant strategy, temperature effect, solvent effect, and additive effect. The method is applied in synthesis of an O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm. A saccharide conjugate can be prepared from the synthesized O-antigen oligosaccharide compound of Helicobacter pylori serotype O2 assembled with an amino linking arm together with a carrier protein for immunology researches, playing an important role in preventing and treating Helicobacter pylori.
Abstract: A malto-dextrin composition with low DE value and low viscosity and the method for making the same is provided. The malto-dextrin comprises a blue value in the range of 0.02 to 0.28; a dextrose equivalent (DE) in the range of 3 to 10; and a viscosity lower than 26.3185*DE{circumflex over (?)}(?0.7593). The method for preparing the malto-dextrin composition comprises: dispersing raw starch in water to obtain a starch-water slurry; preheating the starch-water slurry with a jet-cooker for a first duration at a first temperature above 100° C. having a temperature variation no more than 0.8° C.; hydrolyzing the slurry by treating the slurry with ?-amylases for a second duration at a second temperature; and filtering the hydrolyzed slurry to remove insoluble residual proteins and fibers and obtain an un-fractionated malto-dextrin composition.
Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2?-fucosyllactose (2?FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.
Type:
Grant
Filed:
November 9, 2020
Date of Patent:
December 20, 2022
Assignee:
Glycom A/S
Inventors:
Emma Elison, Bruce McConnell, Thierry Hennet, Louise Kristine Vigsnæs
Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.
Type:
Grant
Filed:
December 8, 2020
Date of Patent:
December 20, 2022
Assignee:
Glycom A/S
Inventors:
Bruce McConnell, Louise Kristine Vigsnæs
Abstract: A compound that includes a dextran backbone having at least one C-type lectin targeting moieties attached thereto. Also disclosed are embodiments of the compound that include at least one therapeutic agent and/or at least one detection label attached to the dextran backbone. The compound may be effective for treatment of Corona Covid-19 (SARS-covid-2) virus, its variants and other related viral diseases, and disorders. Further disclosed are methods for diagnosing and treating diseases and/or disorders directly using the disclosed compounds.
Abstract: Provided herein are compounds, compositions, conjugates and methods for the treatment of diseases, and/or conditions such as, but not limited to, proliferative diseases. In certain embodiments, compounds, compositions, and conjugates are provided, which include cyclodextrin-based linker-payloads and protein conjugates thereof, and/or in combination with other agents. By administering these compounds, compositions, and conjugates as described herein to specific target cells, side-effects due to non-specific binding phenomena, for example, to non-target cells are reduced.
Abstract: The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (?4?1) and alpha-V-beta-3 (? V?3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.
Type:
Grant
Filed:
November 14, 2017
Date of Patent:
November 8, 2022
Assignee:
HOFFMANN-LA ROCHE, INC.
Inventors:
Jayne Chin, Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Achyutharao Sidduri
Abstract: An okra polygalacturonic acid having a uric acid-lowering effect, a method for preparing the same, and use of the same are disclosed. The method includes: smashing an okra, lixiviating the okra in ethanol, and filtering to obtain a filtrate and a residue; removing the filtrate, and lixiviating the residue in heated water to obtain an extraction solution; adding the ethanol into the extraction solution to precipitate okra crude polysaccharides; purifying the okra crude polysaccharides over an anion exchange column by eluting with water or a NaCl solution, a Tris-HCl solution or a NaCl-containing Tris-HCl solution, or a phosphate solution or a NaCl-containing phosphate solution, and collecting a fraction eluted by the NaCl solution, the NaCl-containing Tris-HCl solution, or the NaCl-containing phosphate solution; and concentrating, dialyzing and drying the fraction to obtain the okra polygalacturonic acid.
Type:
Grant
Filed:
December 31, 2020
Date of Patent:
October 25, 2022
Assignee:
Institute of Biological and Medical Engineering, Guangdong Academy of Sciences
Inventors:
Juan Liu, Junjia Chen, Chuanli Lu, Nianfang Ma, Peizi Kang